Nifty
Sensex
:
:
25044.35
82055.11
72.45 (0.29%)
158.32 (0.19%)

Pharmaceuticals & Drugs

Rating :
58/99

BSE: 543245 | NSE: GLAND

1764.90
24-Jun-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1744
  •  1800
  •  1742.1
  •  1744.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  215000
  •  381327086.7
  •  2220.95
  •  1277.8

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 29,104.22
  • 41.67
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 26,817.23
  • 1.02%
  • 3.18

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 4.70%
  • 2.99%
  • FII
  • DII
  • Others
  • 6.9%
  • 32.48%
  • 1.10%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.41
  • 16.56
  • 8.78

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.11
  • 6.89
  • -2.46

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.43
  • -0.01
  • -13.93

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 36.60

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.41

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 17.80

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
46.9
42.4
57.39
70.37
P/E Ratio
37.63
41.63
30.75
25.08
Revenue
5642
5617
6360
7071
EBITDA
1333
1529
1887
Net Income
772
699
938
1147
ROA
8
8.5
9.6
P/B Ratio
3.23
2.89
2.65
ROE
9.26
9.82
10.82
FCFF
718
363
792
FCFF Yield
3.03
1.53
3.35
Net Debt
-1467
-2630
-3228
BVPS
546.13
611
665

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
1,424.91
1,537.45
-7.32%
1,384.05
1,545.15
-10.43%
1,405.83
1,373.42
2.36%
1,401.71
1,208.69
15.97%
Expenses
1,077.39
1,178.80
-8.60%
1,024.10
1,188.76
-13.85%
1,108.78
1,049.35
5.66%
1,137.31
914.74
24.33%
EBITDA
347.52
358.65
-3.10%
359.96
356.39
1.00%
297.06
324.08
-8.34%
264.40
293.95
-10.05%
EBIDTM
24.39%
23.33%
26.01%
23.07%
21.13%
23.60%
18.86%
24.32%
Other Income
44.03
42.15
4.46%
58.49
37.39
56.43%
59.66
53.15
12.25%
51.43
37.54
37.00%
Interest
7.45
9.96
-25.20%
22.82
5.28
332.20%
6.11
6.05
0.99%
5.62
4.92
14.23%
Depreciation
95.76
92.61
3.40%
96.33
105.34
-8.55%
93.83
81.30
15.41%
91.96
65.31
40.81%
PBT
288.33
298.23
-3.32%
299.30
283.16
5.70%
256.78
289.89
-11.42%
218.24
261.27
-16.47%
Tax
101.79
105.81
-3.80%
94.61
91.30
3.63%
93.25
95.81
-2.67%
74.48
67.16
10.90%
PAT
186.54
192.42
-3.06%
204.69
191.86
6.69%
163.53
194.08
-15.74%
143.76
194.10
-25.94%
PATM
13.09%
12.52%
14.79%
12.42%
11.63%
14.13%
10.26%
16.06%
EPS
11.32
11.68
-3.08%
12.42
11.65
6.61%
9.93
11.78
-15.70%
8.73
11.79
-25.95%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Net Sales
5,616.50
5,664.72
3,624.60
4,400.71
3,462.88
2,633.24
Net Sales Growth
-0.85%
56.29%
-17.64%
27.08%
31.51%
 
Cost Of Goods Sold
2,090.38
2,173.09
1,685.42
2,109.11
1,219.00
836.07
Gross Profit
3,526.12
3,491.63
1,939.17
2,291.60
2,243.88
1,797.18
GP Margin
62.78%
61.64%
53.50%
52.07%
64.80%
68.25%
Total Expenditure
4,347.58
4,331.65
2,599.84
2,890.56
2,160.65
1,677.77
Power & Fuel Cost
-
229.99
124.84
95.05
74.58
78.50
% Of Sales
-
4.06%
3.44%
2.16%
2.15%
2.98%
Employee Cost
-
1,256.89
403.26
338.57
311.36
277.66
% Of Sales
-
22.19%
11.13%
7.69%
8.99%
10.54%
Manufacturing Exp.
-
327.19
194.23
179.85
436.84
391.88
% Of Sales
-
5.78%
5.36%
4.09%
12.61%
14.88%
General & Admin Exp.
-
217.36
120.53
94.28
58.66
57.77
% Of Sales
-
3.84%
3.33%
2.14%
1.69%
2.19%
Selling & Distn. Exp.
-
37.46
27.03
40.98
36.69
17.08
% Of Sales
-
0.66%
0.75%
0.93%
1.06%
0.65%
Miscellaneous Exp.
-
89.66
44.53
32.72
23.51
18.82
% Of Sales
-
1.58%
1.23%
0.74%
0.68%
0.71%
EBITDA
1,268.94
1,333.07
1,024.76
1,510.15
1,302.23
955.47
EBITDA Margin
22.59%
23.53%
28.27%
34.32%
37.61%
36.28%
Other Income
213.61
170.24
240.46
223.94
134.78
139.17
Interest
42.00
26.20
7.45
5.24
3.41
7.18
Depreciation
377.88
344.57
146.74
110.30
98.78
94.59
PBT
1,062.65
1,132.54
1,111.04
1,618.55
1,334.81
992.87
Tax
364.13
360.08
273.54
406.89
337.85
220.01
Tax Rate
34.27%
31.79%
25.94%
25.14%
25.31%
22.16%
PAT
698.52
772.46
781.04
1,211.66
996.96
772.86
PAT before Minority Interest
698.52
772.46
781.04
1,211.66
996.96
772.86
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
12.44%
13.64%
21.55%
27.53%
28.79%
29.35%
PAT Growth
-9.57%
-1.10%
-35.54%
21.54%
29.00%
 
EPS
42.39
46.87
47.39
73.52
60.50
46.90

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Shareholder's Funds
8,723.84
7,958.72
7,157.62
5,903.24
3,646.24
Share Capital
16.47
16.47
16.43
16.36
15.49
Total Reserves
8,705.99
7,940.59
7,127.95
5,861.46
3,614.26
Non-Current Liabilities
488.60
89.68
93.97
80.31
80.78
Secured Loans
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
106.54
3.26
3.82
3.93
4.07
Long Term Provisions
137.21
0.00
0.00
0.00
0.00
Current Liabilities
1,398.36
729.13
582.02
512.53
359.02
Trade Payables
862.69
587.35
462.85
396.35
249.09
Other Current Liabilities
425.13
109.48
76.42
62.36
81.73
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
110.54
32.30
42.75
53.82
28.20
Total Liabilities
10,610.80
8,777.53
7,833.61
6,496.08
4,086.04
Net Block
3,946.75
1,570.55
1,502.19
954.23
968.10
Gross Block
5,011.68
2,294.95
2,081.32
1,430.70
1,347.81
Accumulated Depreciation
1,064.93
724.41
579.13
476.46
379.71
Non Current Assets
4,965.66
1,876.73
1,981.54
1,372.44
1,239.75
Capital Work in Progress
237.88
177.22
190.75
337.81
188.47
Non Current Investment
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
773.93
128.96
286.40
77.97
81.52
Other Non Current Assets
7.09
0.00
2.21
2.43
1.66
Current Assets
5,645.15
6,900.81
5,852.08
5,123.64
2,846.29
Current Investments
0.00
0.00
154.87
0.00
0.00
Inventories
1,655.24
1,945.30
1,185.67
1,275.17
756.28
Sundry Debtors
1,558.69
871.39
1,074.81
670.97
601.78
Cash & Bank
1,839.43
3,770.68
3,093.44
3,005.75
1,325.19
Other Current Assets
591.80
91.00
96.75
84.15
163.03
Short Term Loans & Adv.
489.19
222.44
246.55
87.60
91.80
Net Current Assets
4,246.79
6,171.68
5,270.05
4,611.11
2,487.27
Total Assets
10,610.81
8,777.54
7,833.62
6,496.08
4,086.04

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Cash From Operating Activity
996.80
363.97
790.77
604.93
700.93
PBT
1,132.54
1,054.58
1,618.55
1,334.81
992.87
Adjustment
223.60
38.19
-28.27
17.30
32.15
Changes in Working Capital
-53.20
-417.94
-393.01
-435.76
-79.94
Cash after chg. in Working capital
1,302.95
674.83
1,197.28
916.35
945.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-306.15
-310.87
-406.51
-311.43
-244.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,756.91
1,208.19
-1,002.62
-1,524.00
-766.08
Net Fixed Assets
-227.74
-200.10
-503.56
-232.23
Net Investments
-2,377.58
154.87
-162.48
-0.55
Others
848.41
1,253.42
-336.58
-1,291.22
Cash from Financing Activity
-799.42
14.92
34.90
1,238.46
-6.87
Net Cash Inflow / Outflow
-1,559.53
1,587.08
-176.95
319.39
-72.01
Opening Cash & Equivalents
1,908.89
318.82
492.46
169.50
236.40
Closing Cash & Equivalent
357.09
1,908.89
318.82
492.46
169.50

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Book Value (Rs.)
529.56
483.12
434.84
359.30
234.25
ROA
7.97%
9.40%
16.91%
18.84%
18.91%
ROE
9.26%
10.34%
18.61%
20.97%
21.29%
ROCE
13.63%
14.04%
24.85%
28.00%
27.39%
Fixed Asset Turnover
1.55
1.66
2.51
2.49
1.95
Receivable days
78.29
97.99
72.40
67.08
83.41
Inventory Days
116.00
157.65
102.05
107.06
104.83
Payable days
121.78
113.72
74.35
96.63
52.71
Cash Conversion Cycle
72.51
141.92
100.10
77.51
135.53
Total Debt/Equity
0.04
0.00
0.00
0.00
0.00
Interest Cover
44.23
142.61
309.77
392.33
139.24

News Update:


  • Gland Pharma gets EIR from USFDA for Visakhapatnam facility
    24th Jun 2025, 12:00 PM

    The said inspection was conducted between February 19, 2025 and February 25, 2025

    Read More
  • Gland Pharma’s subsidiary gets 11 observations for Fontenay manufacturing facility
    5th Jun 2025, 10:22 AM

    There will be no disruption in the manufacturing operations due to this final inspection report

    Read More
  • Gland Pharma gets USFDA’s approval for Angiotensin II Acetate Injection
    4th Jun 2025, 09:12 AM

    The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA of La Jolla Pharma LLC

    Read More
  • Gland Pharma receives USFDA’s approval for Acetaminophen Injection
    3rd Apr 2025, 12:27 PM

    This product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.